Down-regulation of the miR-25 and miR-30d contributes to the development of anaplastic thyroid carcinoma targeting the polycomb protein EZH2

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 5, 2012, Pages

  Esposito, Francesco ^a   Tornincasa, Mara ^a   Pallante, Pierlorenzo ^a   Federico, Antonella ^a   Borbone, Eleonora ^a,b   Pierantoni, Giovanna Maria ^a   Fusco, Alfredo ^a,b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b Biotecnologie Avanzate   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 25; MICRORNA 30D; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CARCINOGENICITY; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; ENZYME ACTIVITY; ENZYME REGULATION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; THYROID CARCINOMA;

CARCINOMA; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DNA-BINDING PROTEINS; DOWN-REGULATION; GENE EXPRESSION; HUMANS; MICRORNAS; THYROID GLAND; THYROID NEOPLASMS; TRANSCRIPTION FACTORS;

EID: 84860758213     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-3068     Document Type: Article

References (33)

1. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB 2003 Prediction of mammalian microRNA targets. Cell 115:787-798
2. John B, Enright AJ, Aravin A, Tuschl T, Sander C, Marks DS 2004 Human MicroRNA targets. PLoS Biol 2:e363
3. Kiriakidou M, Nelson PT, Kouranov A, Fitziev P, Bouyioukos C, Mourelatos Z, Hatzigeorgiou A 2004 A combined computational experimental approach predicts human microRNA targets. Genes Dev 18:1165-1178
4. Calin GA, Croce CM 2006 MicroRNA signatures in human cancers. Nat Rev Cancer 6:857-866
5. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC, Croce CM 2006 A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 103:2257-2261
6. Visone R, Pallante P, Vecchione A, Cirombella R, Ferracin M, Ferraro A, Volinia S, Coluzzi S, Leone V, Borbone E, Liu CG, Petrocca F, Troncone G, Calin GA, Scarpa A, Colato C, Tallini G, Santoro M, Croce CM, Fusco A 2007 Specific microRNAs are downregulated in human thyroid anaplastic carcinomas. Oncogene 26:7590-7595
7. Poliseno L, Salmena L, Riccardi L, Fornari A, Song MS, Hobbs RM, Sportoletti P, Varmeh S, Egia A, Fedele G, Rameh L, Loda M, Pandolfi PP 2010 Identification of the miR-106b ∼25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation. Sci Signal 3:ra29
8. Birks DK, Barton VN, Donson AM, Handler MH, Vibhakar R, Foreman NK 2011 Survey of microRNA expression in pediatric brain tumors. Pediatr Blood Cancer 56:211-216
9. Yao J, Liang L, Huang S, Ding J, Tan N, Zhao Y, Yan M, Ge C, Zhang Z, Chen T, Wan D, Yao M, Li J, Gu J, He X 2010 MicroRNA-30d promotes tumor invasion and metastasis by targeting Gai2 in hepatocellular carcinoma. Hepatology 51:846-856
10. Yang Y, Li X, Yang Q, Wang X, Zhou Y, Jiang T, Ma Q, Wang YJ 2010 The role of microRNA in human lung squamous cell carcinoma. Cancer Genet Cytogenet 200:127-133
11. Borbone E, Troncone G, Ferraro A, Jasencakova Z, Stojic L, Esposito F, Hornig N, Fusco A, Orlando V 2011 Enhancer of zeste homolog 2 overexpression has a role in the development of anaplastic thyroid carcinomas. J Clin Endocrinol Metab 96:1029-1038
12. Esposito F, Tornincasa M, Chieffi P, De Martino I, Pierantoni GM, Fusco A 2010 High-mobility group A1 proteins regulate p53-mediated transcription of Bcl-2 gene. Cancer Res 70:5379-5388
13. Bracken AP, Pasini D, Capra M, Prosperini E, Colli E, Helin K 2003 EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J 22:5323-5335
14. Bracken AP, Helin K 2009 Polycomb group proteins: navigators of lineage pathways led astray in cancer. Nat Rev Cancer 9:773-784
15. Tang X, Milyavsky M, Shats I, Erez N, Goldfinger N, Rotter V 2004 Activated p53 suppresses the histone methyltransferase EZH2 gene. Oncogene 23:5759-5769
16. Donghi R, Longoni A, Pilotti S, Michieli P, Della Porta G, Pierotti MA 1993 Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. J Clin Invest 91:1753-1760
17. Fagin JA, Matsuo K, Karmakar A, Chen DL, Tang SH, Koeffler HP 1993 High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest 91:179-184
18. Stringer BM, Rowson JM, Parkar MH, Seid JM, Hearn PR, Wynford-Thomas D, Ingemansson S, Woodhouse N, Goyns MH 1989 Detection of the H-RAS oncogene in human thyroid anaplastic carcinomas. Experientia 45:372-376
19. Capella G, Matias-Guiu X, Ampudia X, de Leiva A, Perucho M, Prat J 1996 Ras oncogene mutations in thyroid tumors: polymerase chain reaction-restriction- fragment-length polymorphism analysis from paraffin-embedded tissues. Diagn Mol Pathol 5:45-52
20. Santarpia L, El-Naggar AK, Cote GJ, Myers JN, Sherman SI 2008 Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer. J Clin Endocrinol Metab 93:278-284
21. Garcia-Rostan G, Camp RL, Herrero A, Carcangiu ML, Rimm DL, Tallini G 2001 β-Catenin dysregulation in thyroid neoplasms: down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis. Am J Pathol 158:987-996
22. Tallini G, Garcia-Rostan G, Herrero A, Zelterman D, Viale G, Bosari S, Carcangiu ML 1999 Downregulation of p27KIP1 and Ki67/Mib1 labeling index support the classification of thyroid carcinoma into prognostically relevant categories. Am J Surg Pathol 23:678-685
23. Wiseman SM, Masoudi H, Niblock P, Turbin D, Rajput A, Hay J, Bugis S, Filipenko D, Huntsman D, Gilks B 2007 Anaplastic thyroid carcinoma: expression profile of targets for therapy offers new insights for disease treatment. Ann Surg Oncol 14:719-729
24. Rao AS, Kremenevskaja N, von Wasielewski R, Jakubcakova V, Kant S, Resch J, Brabant G 2006 Wnt/β-catenin signaling mediates antineoplastic effects of imatinib mesylate (gleevec) in anaplastic thyroid cancer. J Clin Endocrinol Metab 91:159-168
25. Lee JJ, Au AY, Foukakis T, Barbaro M, Kiss N, Clifton-Bligh R, Staaf J, Borg A, Delbridge L, Robinson BG, Wallin G, Hoög A, Larsson C 2008 Array-CGH identifies cyclin D1 and UBCH10 amplicons in anaplastic thyroid carcinoma. Endocr Relat Cancer 15:801-815
26. Levine SS, Weiss A, Erdjument-Bromage H, Shao Z, Tempst P, Kingston RE 2002 The core of the polycomb repressive complex is compositionally and functionally conserved in flies and humans. Mol Cell Biol 22:6070-6078
27. Rastelli L, Chan CS, Pirrotta V 1993 Related chromosome binding sites for zeste, suppressors of zeste and Polycomb group proteins in Drosophila and their dependence on Enhancer of zeste function. EMBO J 12:1513-1522
28. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, Rubin MA, Chinnaiyan AM 2002 The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419:624-629
29. Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, Ghosh D, Sewalt RG, Otte AP, Hayes DF, Sabel MS, Livant D, Weiss SJ, Rubin MA, Chinnaiyan AM 2003 EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA 100:11606-11611
30. Varambally S, Cao Q, Mani RS, Shankar S, Wang X, Ateeq B, Laxman B, Cao X, Jing X, Ramnarayanan K, Brenner JC, Yu J, Kim JH, Han B, Tan P, Kumar-Sinha C, Lonigro RJ, Palanisamy N, Maher CA, Chinnaiyan AM 2008 Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 322:1695-1699
31. Bohrer LR, Chen S, Hallstrom TC, Huang H 2010 Androgens suppress EZH2 expression via retinoblastoma (RB) and p130-dependent pathways: a potential mechanism of androgen-refractory progression of prostate cancer. Endocrinology 151:5136-5145
32. Min J, Zaslavsky A, Fedele G, McLaughlin SK, Reczek EE, De Raedt T, Guney I, Strochlic DE, Macconaill LE, Beroukhim R, Bronson RT, Ryeom S, Hahn WC, Loda M, Cichowski K 2010 An oncogenetumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-KB. Nat Med 16:286-294
33. Li Y, Tan W, Neo TW, Aung MO, Wasser S, Lim SG, Tan TM 2009 Role of the miR-106b-25 microRNA cluster in hepatocellular carcinoma. Cancer Sci 100:1234-1242